DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Autoimmune Partnering 2010-2017: Deal trends, players and financials" report to their offering.
Global Autoimmune Partnering 2010 to 2017 provides the full collection of Autoimmune disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Autoimmune disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Autoimmune deals.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in Autoimmune dealmaking
Chapter 3 -Financial deal terms for Autoimmune partnering
Chapter 4 - Leading Autoimmune deals and dealmakers
Chapter 5 - Autoimmune contract document directory
Chapter 6 - Autoimmune dealmaking by therapeutic target
For more information about this report visit http://www.researchandmarkets.com/research/7v7qzq/global_autoimmune